DOP2015000284A - Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos - Google Patents

Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos

Info

Publication number
DOP2015000284A
DOP2015000284A DO2015000284A DO2015000284A DOP2015000284A DO P2015000284 A DOP2015000284 A DO P2015000284A DO 2015000284 A DO2015000284 A DO 2015000284A DO 2015000284 A DO2015000284 A DO 2015000284A DO P2015000284 A DOP2015000284 A DO P2015000284A
Authority
DO
Dominican Republic
Prior art keywords
systems
supply
active agents
methods
compositions
Prior art date
Application number
DO2015000284A
Other languages
English (en)
Inventor
Vidya B Joshi
Colin Reisner
Patrick Fitzgerald Darken
David Lechuga-Ballesteros
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of DOP2015000284A publication Critical patent/DOP2015000284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS, SISTEMAS Y MÉTODOS ADECUADOS PARA EL SUMINISTRO POR VÍA RESPIRATORIA DE UNA COMBINACIÓN FIJA DE LOS AGENTES ACTIVOS LAMA, LABA, E ICS. LAS COMPOSICIONES FARMACÉUTICAS DESCRITAS EN EL PRESENTE DOCUMENTO PUEDEN FORMULARSE PARA EL SUMINISTRO POR VÍA RESPIRATORIA A TRAVÉS DE UN INHALADOR DE DOSIS MEDIDA (MDI). TAMBIÉN SE DESCRIBEN EN EL PRESENTE DOCUMENTO SISTEMAS DE MDI PARA LA ADMINISTRACIÓN DE UNA COMBINACIÓN FIJA DE LOS AGENTES ACTIVOS LAMA, LABA, E ICS, ASÍ COMO TAMBIÉN SE DESCRIBEN MÉTODOS PARA PREPARAR Y USAR LAS COMPOSICIONES Y LOS SISTEMAS DESCRITOS EN EL PRESENTE DOCUMENTO.
DO2015000284A 2013-05-22 2015-11-20 Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos DOP2015000284A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361826424P 2013-05-22 2013-05-22

Publications (1)

Publication Number Publication Date
DOP2015000284A true DOP2015000284A (es) 2016-04-29

Family

ID=50942948

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000284A DOP2015000284A (es) 2013-05-22 2015-11-20 Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos

Country Status (20)

Country Link
US (1) US20150150787A1 (es)
EP (1) EP2999460A1 (es)
JP (1) JP2016519160A (es)
KR (1) KR20160013134A (es)
CN (1) CN105392471A (es)
AU (1) AU2014268482A1 (es)
BR (1) BR112015028964A2 (es)
CA (1) CA2912927A1 (es)
CL (1) CL2015003422A1 (es)
CR (1) CR20150645A (es)
DO (1) DOP2015000284A (es)
HK (2) HK1221653A1 (es)
MX (1) MX2015016058A (es)
NI (1) NI201500163A (es)
PE (1) PE20160155A1 (es)
PH (1) PH12015502593A1 (es)
RU (1) RU2015154720A (es)
SG (1) SG11201509543YA (es)
WO (1) WO2014190204A1 (es)
ZA (1) ZA201509016B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2763939A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
MX351993B (es) * 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
JP6397025B2 (ja) * 2013-11-22 2018-09-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド 吸引可能薬剤
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
US20220000881A1 (en) * 2018-10-31 2022-01-06 Repurposed Therapeutics, Inc. Dba Defender Treatment of exposure to chlorine gas with scopolamine
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN111617138A (zh) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用
IL309888A (en) * 2021-07-09 2024-03-01 Astrazeneca Pharmaceuticals Lp Aerosol drug delivery compounds, methods and systems
WO2023119093A1 (en) * 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
DE69634246T2 (de) 1995-04-14 2006-01-12 Nektar Therapeutics, San Carlos Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
PT102343B (pt) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
PT1666028E (pt) 1999-10-29 2010-06-15 Novartis Ag Composições de pós anidros com melhor dispersividade
JP2007500234A (ja) 2003-05-28 2007-01-11 ネクター セラピューティクス 水に不溶な活性剤を含む医薬的成形
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2763939A1 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
CA2827045A1 (en) * 2011-02-17 2012-08-23 Cipla Limited Compositions of glycopyrrolate and a beta2-agonist
EP2709447A4 (en) * 2011-05-17 2014-10-22 Pearl Therapeutics Inc COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY ADMINISTRATION OF AT LEAST TWO ACTIVE AGENTS

Also Published As

Publication number Publication date
ZA201509016B (en) 2018-07-25
KR20160013134A (ko) 2016-02-03
CA2912927A1 (en) 2014-11-27
MX2015016058A (es) 2016-12-20
SG11201509543YA (en) 2015-12-30
RU2015154720A (ru) 2017-06-27
HK1221653A1 (zh) 2017-06-09
PE20160155A1 (es) 2016-04-01
CL2015003422A1 (es) 2016-09-02
PH12015502593A1 (en) 2016-02-29
AU2014268482A1 (en) 2016-01-07
BR112015028964A2 (pt) 2017-07-25
WO2014190204A1 (en) 2014-11-27
JP2016519160A (ja) 2016-06-30
CR20150645A (es) 2016-02-10
EP2999460A1 (en) 2016-03-30
US20150150787A1 (en) 2015-06-04
NI201500163A (es) 2016-01-06
CN105392471A (zh) 2016-03-09
HK1221654A1 (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
DOP2015000284A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000381A1 (es) Compuestos antivirales
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
UY35210A (es) Inhibidores de autotaxina
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
BR112014030060A2 (pt) compostos de tetra-hidropirazolopirimidina
TR201908596T4 (tr) Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları.
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112016002459A2 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
PE20151979A1 (es) Compuestos quimicos
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
CR20150440A (es) Nuevos derivados de piridina